Development Pipeline as at 31 December 2017  or directed trials Phase III Pivotal Phase II Registration New Molecular Entities NMEs and significant additional indications Regulatory submission dates shown for assets in Phase III and beyond.
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Date Estimated Regulatory Acceptance Date Submission Status Area Under Commenced Compound Mechanism Investigation Phase US EU Japan China Oncology # Calquence acalabrutinib BTK inhibitor B-cell malignancy Q1 2015 Launched # savolitinib SAVOIR MET inhibitor papillary renal cell carcinoma Q3 2017 2020 2020 selumetinib ASTRA MEK inhibitor differentiated thyroid cancer Q3 2013 H2 2018 H2 2018 Orphan Drug Designation # moxetumomab pasudotox anti-CD22 hairy cell leukaemia Q2 2013 H1 2018 Orphan Drug Designation PLAIT recombinant immunotoxin # Imfinzi tremelimumab PD-L1 mAb 3rd line NSCLC Q2 2015 H1 2018 H1 2018 H1 2018 ARCTIC CTLA-4 mAb # Imfinzi tremelimumab PD-L1 mAb 1st line NSCLC Q3 2015 H2 2018 H2 2018 H2 2018 MYSTIC CTLA-4 mAb # Imfinzi tremelimumab PD-L1 mAb 1st line NSCLC Q4 2015 2019 2019 2019 2020 NEPTUNE CTLA-4 mAb # Imfinzi tremelimumab PD-L1 mAb 1st line NSCLC Q2 2017 2019 2019 2019 2020 chemotherapy CTLA-4 mAb POSEIDON # Imfinzi tremelimumab SoC PD-L1 mAb 1st line SCLC Q1 2017 2019 2019 2019 CASPIAN CTLA-4 mAb SoC # Imfinzi tremelimumab PD-L1 mAb 1st line HNSCC Q4 2015 H2 2018 H2 2018 H2 2018 KESTREL CTLA-4 mAb # Imfinzi tremelimumab PD-L1 mAb 2nd line HNSCC Q4 2015 H2 2018 H2 2018 H2 2018 EAGLE CTLA-4 mAb # Imfinzi tremelimumab PD-L1 mAb 1st line bladder cancer Q4 2015 2019 2019 2019 DANUBE CTLA-4 mAb # Imfinzi tremelimumab PD-L1 mAb 1st line hepatocellular Q4 2017 2021 2021 2021 2021 HIMALAYA CTLA-4 mAb carcinoma # Lynparza cediranib PARP inhibitor recurrent platinum-resistant Q1 2017 2019 CONCERTO VEGF inhibitor ovarian cancer CVMD Epanova omega-3 severe  Approved 2020 carboxylic acids 1 ZS-9 sodium zirconium potassium binder hyperkalaemia Accepted 2019 cyclosilicate # 2 roxadustat hypoxia-inducible anaemia in CKD end-stage Q3 2014 H2 2018 Accepted OLYMPUS US factor prolyl renal disease ROCKIES US hydroxylase inhibitor 202 AstraZeneca Annual Report & Form 20-F Information 2017 Additional Information Additional Information Date Estimated Regulatory Acceptance Date Submission Status Area Under Commenced Compound Mechanism Investigation Phase US EU Japan China Respiratory Bevespi PT003 LABA LAMA COPD Launched Accepted H2 2018 H2 2018 # # Fasenra benralizumab IL-5R mAb severe, Launched Approved Approved 2021 CALIMA uncontrolled asthma SIROCCO ZONDA BISEBORA GREGALE PT010 LABA LAMA ICS COPD Q3 2015 2019 2019 H2 2018 H2 2018 tezepelumab TSLP mAb severe, Q1 2018 2021 2021 2021 NAVIGATOR uncontrolled asthma SOURCE Other # anifrolumab Type 1 IFN systemic lupus erythematosus Q3 2015 2019 2019 2019 TULIP receptor mAb Fast Track # lanabecestat beta-secretase Alzheimers disease Q2 2016 2020 2020 2020 AMARANTH extension, inhibitor Fast Track DAYBREAK-ALZ # Collaboration.
2 FibroGen completed rolling regulatory submission in China.
Phases I and II NMEs and significant additional indications Date Commenced Compound Mechanism Area Under Investigation Phase Phase Oncology # Imfinzi PD-L1 mAb solid tumours II Q3 2014 # Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb gastric cancer II Q2 2015 # Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb biliary tract, oesophageal II Q4 2013 # Imfinzi tremelimumab chemo PD-L1 mAb CTLA-4 mAb 1st line pancreatic ductal adenocarcinoma, I Q2 2016 oesophageal and SCLC # Imfinzi AZD5069 PD-L1 mAb CXCR2 antagonist pancreatic ductal adenocarcinoma II Q2 2017 # # # Imfinzi AZD5069 or Imfinzi AZD9150 PD-L1 mAb CXCR2 antagonist or HNSCC II Q3 2015 PD-L1 mAb STAT3 inhibitor # Imfinzi dabrafenib trametinib PD-L1 mAb BRAF inhibitor MEK inhibitor melanoma I Q1 2014 # # Imfinzi AZD1775 PD-L1 mAb Wee1 inhibitor solid tumours I Q4 2015 # Imfinzi MEDI0680 PD-L1 mAb PD-1 mAb solid tumours II Q3 2016 # # Imfinzi or Imfinzi PD-L1 mAb or PD-L1 mAb diffuse large B-cell lymphoma I Q3 2016 # tremelimumab or AZD9150 CTLA-4 mAb or STAT3 inhibitor # Imfinzi Iressa PD-L1 mAb EGFR inhibitor NSCLC I Q2 2014 # # Imfinzi MEDI0562 PD-L1 mAb humanised OX40 agonist solid tumours I Q2 2016 # # Imfinzi MEDI9197 PD-L1 mAb TLR 7 8 agonist solid tumours I Q2 2017 # Imfinzi oleclumab MEDI9447 PD-L1 mAb CD73 mAb solid tumours I Q1 2016 # Imfinzi monalizumab PD-L1 mAb NKG2a mAb solid tumours I Q1 2016 # Imfinzi selumetinib PD-L1 mAb MEK inhibitor solid tumours I Q4 2015 # Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb solid tumours I Q4 2013 # tremelimumab MEDI0562 CTLA-4 mAb humanised OX40 agonist solid tumours I Q2 2016 # Imfinzi azacitidine PD-L1 mAb azacitidine myelodysplastic syndrome I Q2 2016 AstraZeneca Annual Report & Form 20-F Information 2017 Development Pipeline 203 Development Pipeline continued Date Commenced Compound Mechanism Area Under Investigation Phase Phase # # Imfinzi MEDI0457 PD-L1 mAb DNA HPV vaccine HNSCC II Q4 2017 # Imfinzi RT platform PD-L1 mAb RT locally-advanced HNSCC, NSCLC, SCLC I Q1 2018 CLOVER # Lynparza AZD6738 PARP inhibitor ATR inhibitor gastric cancer II Q3 2016 # # Lynparza AZD1775 PARP inhibitor Wee1 inhibitor solid tumours I Q3 2015 # # Lynparza Imfinzi PARP inhibitor PD-L1 mAb solid tumours II Q2 2016 MEDIOLA # # Tagrisso selumetinib or savolitinib EGFR inhibitor MEK inhibitor or advanced EGFRm NSCLC II Q2 2016 TATTON MET inhibitor Tagrisso EGFR inhibitor CNS metastases in advanced II Q4 2015 BLOOM EGFRm NSCLC # AZD1775 chemotherapy Wee1 inhibitor chemotherapy ovarian cancer II Q1 2015 # AZD1775 Wee1 inhibitor solid tumours I Q3 2015 vistusertib mTOR inhibitor solid tumours II Q1 2013 # AZD5363 AKT inhibitor breast cancer II Q1 2014 AZD4547 FGFR inhibitor solid tumours II Q4 2011 AZD0156 ATM inhibitor solid tumours I Q4 2015 AZD1390 ATM inhibitor healthy volunteer trial I Q4 2017 # AZD2811 Aurora B inhibitor solid tumours I Q4 2015 AZD4573 CDK9 inhibitor haematological malignancies I Q4 2017 AZD4635 A2aR inhibitor solid tumours I Q2 2016 AZD4785 KRAS inhibitor solid tumours I Q2 2017 AZD5153 BRD4 inhibitor solid tumours I Q3 2017 AZD5991 MCL1 inhibitor haematological malignancies I Q3 2017 Calquence vistusertib B-cell malignancy mTor inhibitor haematological malignancies I Q3 2017 AZD6738 ATR inhibitor solid tumours I Q4 2013 AZD8186 PI3k inhibitor solid tumours I Q2 2013 AZD9496 selective oestrogen receptor degrader oestrogen receptor five breast cancer I Q4 2014 # MEDI-565 CEA BiTE mAb solid tumours I Q1 2011 # MEDI0562 humanised OX40 agonist solid tumours I Q1 2015 MEDI1873 GITR agonist fusion protein solid tumours I Q4 2015 # MEDI3726 PSMA antibody drug conjugate prostate cancer I Q1 2017 MEDI4276 HER2 bi-specific antibody drug conjugate solid tumours I Q4 2015 MEDI5083 immune activator solid tumours I Q1 2017 MEDI7247 antibody drug conjugate haematological malignancies I Q2 2017 # MEDI9197 TLR 7 8 agonist solid tumours I Q4 2015 oleclumab MEDI9447 CD73 mAb solid tumours I Q3 2015 CVMD verinurad URAT1 inhibitor CKD II Q2 2017 MEDI0382 GLP-1 glucagon dual agonist Type 2 diabetes obesity II Q3 2016 MEDI6012 LCAT CV disease II Q4 2015 AZD4831 myeloperoxidase HF with a preserved ejection fraction I Q3 2016 AZD5718 FLAP coronary artery disease II Q4 2017 # AZD8601 VEGF-A CV disease I Q1 2017 # MEDI5884 cholesterol modulation CV disease II Q4 2017 Respiratory # abediterol LABA asthma COPD II Q4 2007 # tezepelumab TSLP mAb atopic dermatitis II Q2 2015 # AZD1419 inhaled TLR9 agonist asthma II Q4 2016 AZD7594 inhaled SGRM asthma COPD II Q3 2015 # AZD8871 MABA COPD II Q1 2017 PT010 LABA LAMA ICS asthma II Q2 2014 AZD5634 inhaled ENaC cystic fibrosis I Q1 2016 # AZD7594 abediterol inhaled SGRM LABA asthma COPD I Q4 2016 # AZD7986 DPP1 COPD II Q4 2017 AZD9567 oral SGRM rheumatoid arthritis respiratory II Q4 2015 # AZD1402 inhaled IL-4Ra asthma I Q4 2017 MEDI3506 IL-33 mAb COPD I Q2 2017 204 AstraZeneca Annual Report & Form 20-F Information 2017 Additional Information Additional Information Date Commenced Compound Mechanism Area Under Investigation Phase Phase Other # anifrolumab Type 1 IFN receptor mAb lupus nephritis II Q4 2015 # anifrolumab Type 1 IFN receptor mAb systemic lupus erythematosus II Q1 2017 subcutaneous # inebilizumab CD19 mAb neuromyelitis optica II Q1 2015 Orphan drug US, EU # mavrilimumab GM-CSFR mAb rheumatoid arthritis II Q1 2010 MEDI3902 Psl PcrV bispecific mAb prevention of nosocomial pseudomonas II Q2 2016 Fast Track, US aeruginosa pneumonia suvratoxumab MEDI4893 mAb binding to S. aureus toxin prevention of nosocomial Staphylococcus II Q4 2014 Fast Track, US aureus pneumonia # # prezalumab MEDI5872 B7RP1 mAb primary Sjgrens syndrome II Q3 2015 MEDI8852 influenza A mAb influenza A treatment II Q4 2015 Fast Track, US # MEDI8897 RSV mAb-YTE passive RSV prophylaxis II Q1 2015 Fast Track, US AZD0284 RORg psoriasis respiratory I Q4 2016 # MEDI0700 BAFF B7RP1 bispecific mAb systemic lupus erythematosus I Q1 2016 # MEDI1814 amyloid beta mAb Alzheimers disease I Q2 2014 MEDI4920 anti-CD40L-Tn3 fusion protein primary Sjgrens syndrome I Q2 2014 MEDI7352 NGF TNF bi-specific mAb osteoarthritis pain I Q1 2016 MEDI7734 ILT7 mAb myositis I Q3 2016 MEDI9314 IL-4R mAb atopic dermatitis I Q1 2016 # Collaboration.
Significant Life-cycle Management Date Estimated Regulatory Acceptance Date Submission Status Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China Oncology # Calquence acalabrutinib BTK inhibitor 1st line chronic lymphocytic Q3 2015 2020 2020 Orphan Drug Orphan leukaemia Designation designation # Calquence acalabrutinib BTK inhibitor relapsed refractory chronic Q4 2015 2019 2019 Orphan Drug Orphan lymphocytic leukaemia, Designation designation high risk # Calquence acalabrutinib BTK inhibitor 1st line mantle cell lymphoma Q1 2017 2023 Faslodex FALCON oestrogen receptor 1st line hormone receptor five Approved Approved Approved Approved antagonist advanced breast cancer # Imfinzi PACIFIC PD-L1 mAb locally-advanced Stage 3, Q2 2014 Accepted Accepted Accepted Breakthrough NSCLC Therapy Designation & Priority Review # Imfinzi PEARL China PD-L1 mAb 1st line NSCLC Q1 2017 2020 # Lynparza OlympiAD PARP inhibitor gBRCA metastatic Q2 2014 Approved H1 2018 Accepted H2 2018 Priority Review Orphan drug breast cancer designation, Priority Review # Approved Lynparza SOLO-2 PARP inhibitor 2nd line or greater BRCAm Q3 2013 Accepted Approved Accepted Priority Review Orphan drug PSR ovarian cancer, designation maintenance monotherapy # Lynparza SOLO-1 PARP inhibitor 1st line BRCAm ovarian cancer Q3 2013 H2 2018 H2 2018 H2 2018 2019 # Lynparza SOLO-3 PARP inhibitor gBRCA PSR ovarian cancer Q1 2015 H2 2018 # Lynparza POLO PARP inhibitor pancreatic cancer Q1 2015 2019 2019 # Lynparza PROfound PARP inhibitor prostate cancer Q1 2017 2020 2020 2020 2020 Breakthrough Therapy Designation # Lynparza OlympiA PARP inhibitor gBRCA adjuvant breast cancer Q2 2014 2020 2020 2020 Tagrisso FLAURA EGFR inhibitor 1st line advanced EGFRm Q1 2015 Accepted Accepted Accepted H2 2018 Breakthrough NSCLC Therapy Designation Tagrisso ADAURA EGFR inhibitor adjuvant EGFRm NSCLC Q4 2015 2022 2022 2022 2022 AstraZeneca Annual Report & Form 20-F Information 2017 Development Pipeline 205 Development Pipeline continued Date Estimated Regulatory Acceptance Date Submission Status Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China CVMD 1 Brilinta THALES P2Y12 receptor acute ischaemic stroke or Q1 2018 2020 2020 2020 2020 antagonist transient ischaemic attack 1 Brilinta THEMIS P2Y12 receptor CV outcomes trial in patients Q1 2014 2019 2019 2019 2020 antagonist with Type 2 diabetes and coronary artery disease without a previous history of MI or stroke 1 Brilinta HESTIA P2Y12 receptor prevention of vaso-occlusive Q1 2014 2021 2021 antagonist crises in paediatric patients with sickle cell disease 2 Farxiga DECLARE-TIMI 58 SGLT2 inhibitor CV outcomes trial in patients Q2 2013 2019 2019 with Type 2 diabetes 2 Farxiga SGLT2 inhibitor Type 1 diabetes Q4 2014 H2 2018 H1 2018 H2 2018 2 Farxiga SGLT2 inhibitor worsening HF or CV death Q1 2017 2020 2020 2020 2020 in patients with chronic HF 2 Farxiga SGLT2 inhibitor renal outcomes and CV Q1 2017 2021 2021 n a 2021 mortality in patients with CKD 3 Xigduo XR Xigduo SGLT2 inhibitor Type 2 diabetes Launched Launched 2020 metformin FDC Qtern DPP-4 inhibitor Type 2 diabetes Launched Launched SGLT2 inhibitor FDC Bydureon BCise Bydureon GLP-1 receptor Type 2 diabetes Q1 2013 Launched Accepted 4 autoinjector agonist Bydureon EXSCEL GLP-1 receptor Type 2 diabetes outcomes trial Q2 2010 H1 2018 H1 2018 H2 2018 agonist saxagliptin dapagliflozin DPP-4 inhibitor Type 2 diabetes Q2 2017 H1 2018 H1 2018 metformin SGLT2 inhibitor Epanova STRENGTH omega-3 CV outcomes trial in Q4 2014 2020 2020 2020 2020 carboxylic acids statin-treated patients at high CV risk, with persistent  plus low HDL-cholesterol Respiratory # # Fasenra benralizumab IL-5R mAb COPD Q3 2014 H2 2018 H2 2018 2019 TERRANOVA GALATHEA Symbicort SYGMA ICS LABA as-needed use in mild asthma Q4 2014 2018 2019 # Duaklir Genuair LAMA LABA COPD H1 2018 Launched 2019 Other Nexium proton-pump stress ulcer prophylaxis Accepted inhibitor Nexium proton-pump paediatrics Launched Launched Approved inhibitor # linaclotide GC-C receptor irritable bowel syndrome Accepted peptide agonist with constipation IBS-C # Collaboration.
1 Brilinta in the US and Japan: Brilique in ROW.
2 Farxiga in the US: Forxiga in ROW.
3 Xigduo XR in the US: Xigduo in the EU.
4 Bydureon BCise in the US: Bydureon autoinjector in the EU.
206 AstraZeneca Annual Report & Form 20-F Information 2017 Additional Information Additional Information Terminations Discontinued projects NME Line Extension Compound Reason for Discontinuation Area Under Investigation Symbicort breath actuated inhaler ICS LABA Strategic asthma COPD AZD3241 myeloperoxidase inhibitor Safety efficacy multiple system atrophy # AZD9412 inhaled interferon beta Strategic asthma COPD AZD4076 anti-miR103 107 oligonucleotide Safety efficacy non-alcoholic fatty liver disease non-alcoholic steatohepatitis NASH MEDI4166 PCSK9 GLP-1 mAb peptide fusion Safety efficacy diabetes cardiovascular verinurad selective uric acid reabsorption inhibitor URAT-1 Strategic chronic treatment of hyperuricemia in patients NME MEDI8111 Strategic trauma bleeding # NME AZD9898 Safety efficacy asthma NME MEDI-573 Safety efficacy metastatic breast cancer NME tralokinumab Safety efficacy severe, uncontrolled asthma STRATOS 1,2 TROPOS MESOS # Collaboration.
Completed Projects Divestitures Estimated Regulatory Submission Acceptance Area Under Completed Compound Mechanism Investigation Divested US EU Japan China Tagrisso AURA, AURA2, EGFR inhibitor 2nd line advanced Completed Launched Launched Launched Launched Breakthrough Accelerated AURA17 Asia regional EGFRm T790M Therapy, assessment NSCLC Priority Review, Orphan drug Tagrisso AURA3 EGFR inhibitor 2nd line advanced Completed Launched Launched EGFRm T790M NSCLC Brilinta Brilique P2Y12 receptor arterial thrombosis Completed Launched Launched Launched Launched antagonist Onglyza SAVOR-TIMI 53 DPP-4 inhibitor Type 2 diabetes Completed Launched Launched Launched Onglyza outcomes trial SAVOR-TIMI 53 Farxiga Forxiga SGLT2 inhibitor Type 2 diabetes Completed Launched Launched Launched Launched # Imfinzi durvalumab PD-L1 mAb 2nd line advanced Completed Approved, n a n a n a bladder cancer Launched Breakthrough Therapy & Priority Review AZD9150 STAT3 inhibitor haematological Completed malignancies MEDI0680 PD-1 mAb solid tumours Completed 1 Kombiglyze XR Komboglyze DPP-4 inhibitor Type 2 diabetes Launched Launched Launched metformin FDC # Collaboration.
1 Kombiglyze XR in the US: Komboglyze in the ROW.
AstraZeneca Annual Report & Form 20-F Information 2017 Development Pipeline 207
